GT Biopharma Revenue and Competitors
Estimated Revenue & Valuation
- GT Biopharma's estimated annual revenue is currently $697.5k per year.
- GT Biopharma's estimated revenue per employee is $77,500
Employee Data
- GT Biopharma has 9 Employees.
- GT Biopharma grew their employee count by 29% last year.
GT Biopharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Consulting Chief Scientific Officer | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Vice Chairman the Board | Reveal Email/Phone |
5 | Executive Chairman, Board Directors | Reveal Email/Phone |
GT Biopharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is GT Biopharma?
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology. (NASDAQ: GTBP)
keywords:N/A
N/A
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
29%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Beverly Hills
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A |
#2 | $0.7M | 9 | 0% | N/A |
#3 | $1.3M | 9 | N/A | N/A |
#4 | $1.7M | 9 | 0% | $1M |
#5 | $0.9M | 10 | 0% | N/A |